Danaher Corp (NYSE:DHR) stock rose 0.93% (As on July 24, 11:23:03 AM UTC-4, Source: Google Finance) after the company reported a solid performance in the second quarter of 2024, with both earnings and revenue surpassing analyst expectations. Biotechnology sales fell 9% from $1.86 billion to $1.71 billion. Life Sciences segment sales decreased slightly from $1.79 billion to $1.77 billion. Diagnostic sales increased from $2.23 billion to $2.26 billion. The operating margin of 27.3% came in above the guidance of around 26%. Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.
DHR in the second quarter of FY 24 has reported the adjusted earnings per share of $1.72, beating the analysts’ estimates for the adjusted earnings per share of $1.57. The company had reported the adjusted revenue decline of 3 percent to $5.7 billion in the second quarter of FY 24, beating the analysts’ estimates for revenue of $5.59 billion.
For the third quarter 2024, the Company anticipates that non-GAAP core revenue will be down low-single digits year-over-year. For full year 2024, the Company continues to expect that non-GAAP core revenue will be down low-single digits year-over-year. The company forecasts a third-quarter adjusted operating margin of around 26% and reaffirms fiscal year 2024 margin guidance of ~29%. The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around $1.6 billion.
On the other hand, the company has recently announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). CDx and CoDx tests enable patients to receive targeted therapies intended to better treat their disease. CDx tests are designed to determine whether a patient produces enough of a particular protein to respond well to a specific drug. CoDx tests highlight broadly which type of therapy may be most helpful to a patient. For patients undergoing cancer treatment, this diagnostic process can make a significant difference in prognosis. Danaher’s first CLIA CAP lab, scheduled to open in July in Newcastle, UK, will serve as a hub for collaborative research with leading pharmaceutical and academic institutions. Leica Biosystems, a global leader in anatomic pathology and a Danaher subsidiary, is hosting the lab in a state-of-the-art new building on its campus.